Ryan Merkow to Neoadjuvant Therapy
This is a "connection" page, showing publications Ryan Merkow has written about Neoadjuvant Therapy.
Connection Strength
1.042
-
Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. Ann Surg Oncol. 2012 Feb; 19(2):357-64.
Score: 0.312
-
Neoadjuvant therapy use and association with postoperative outcomes and overall survival in patients with extrahepatic cholangiocarcinoma. J Surg Oncol. 2023 Jan; 127(1):90-98.
Score: 0.169
-
Margin Positivity in Resectable Esophageal Cancer: Are there Modifiable Risk Factors? Ann Surg Oncol. 2020 May; 27(5):1496-1507.
Score: 0.140
-
The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S500-8.
Score: 0.087
-
Effect of including cancer-specific variables on risk-adjusted hospital surgical quality comparisons. Ann Surg Oncol. 2013 Jun; 20(6):1766-73.
Score: 0.087
-
Effect of including cancer-specific variables on models examining short-term outcomes. Cancer. 2013 Apr 01; 119(7):1412-9.
Score: 0.086
-
Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States. Ann Surg Oncol. 2013 Feb; 20(2):362-70.
Score: 0.084
-
Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States. Ann Surg Oncol. 2012 Jan; 19(1):184-91.
Score: 0.078